The company said the board increased its size from 9 to 10 members on May 8, 2024 and appointed Cheryl Pegus, MD, MPH, as a director, and she will also serve on the Executive Compensation and Human Resources Committee and the Risk Committee.

1. 01

   The company said the board increased its size from 9 to 10 members on May 8, 2024 and appointed Cheryl Pegus, MD, MPH, as a director, and she will also serve on the Executive Compensation and Human Resources Committee and the Risk Committee.

2. 02

   The company said it will pay Ms. Pegus a prorated cash retainer of about $122,950 and equity valued at about $211,474 through its 2025 annual meeting of stockholders. The equity vests at the end of her term, and the grant date is June 3, 2024.

3. 03

   The company entered into the 3 amendment to its May 10, 2024 $2.750 billion revolving credit agreement, extending the maturity date for consenting lenders from May 10, 2027 to May 10, 2029.

4. 04

   The company reset the date for restructuring-related charges that can be excluded from Consolidated EBITDA under its Maximum Leverage Ratio covenant from December 31, 2022 to March 31, 2024. The aggregate amount of those charges since that date may not exceed $500,000,000.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.